Bank of New York Mellon Corp Increases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bank of New York Mellon Corp grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,621,344 shares of the company’s stock after buying an additional 67,571 shares during the period. Bank of New York Mellon Corp owned 0.14% of Teva Pharmaceutical Industries worth $35,734,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $2,868,000. Union Bancaire Privee UBP SA purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $446,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in Teva Pharmaceutical Industries by 2.4% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 311,143 shares of the company’s stock worth $6,858,000 after buying an additional 7,193 shares in the last quarter. Finally, TCW Group Inc. increased its position in Teva Pharmaceutical Industries by 52.8% in the fourth quarter. TCW Group Inc. now owns 109,097 shares of the company’s stock worth $2,404,000 after buying an additional 37,707 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.1 %

Teva Pharmaceutical Industries stock opened at $15.34 on Friday. The firm has a market capitalization of $17.40 billion, a P/E ratio of -10.58, a P/E/G ratio of 1.44 and a beta of 0.71. The stock’s fifty day simple moving average is $18.85 and its 200-day simple moving average is $18.38. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Friday. Finally, UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.